Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment

Infect Dis Now. 2021 May;51(3):311-313. doi: 10.1016/j.idnow.2020.10.010. Epub 2020 Dec 30.

Authors

Guangqiang Meng¹, Jingshi Wang¹, Yini Wang¹, Zhao Wang²

Affiliations

¹ Department of hematology, Beijing Friendship Hospital, Capital Medical University, 100050 Beijing, China.
² Department of hematology, Beijing Friendship Hospital, Capital Medical University, 100050 Beijing, China. Electronic address: wangzhao@ccmu.edu.cn.

PMID: 33934812
DOI: 10.1016/j.idnow.2020.10.010

No abstract available

Keywords: Cytomegalovirus; Hemophagocytic lymphohistiocytosis; Ruxolitinib.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antiviral Agents / therapeutic use
Cytomegalovirus / isolation & purification
Cytomegalovirus Infections / complications*
Cytomegalovirus Infections / diagnosis
Cytomegalovirus Infections / drug therapy
DNA, Viral / isolation & purification
Female
Ganciclovir / therapeutic use
Humans
Immunologic Factors / therapeutic use
Immunosuppressive Agents / therapeutic use
Lung Diseases, Interstitial / complications
Lung Diseases, Interstitial / drug therapy
Lymphohistiocytosis, Hemophagocytic / diagnosis
Lymphohistiocytosis, Hemophagocytic / drug therapy*
Lymphohistiocytosis, Hemophagocytic / virology*
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines
Treatment Outcome

Substances

Antiviral Agents
DNA, Viral
Immunologic Factors
Immunosuppressive Agents
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
Ganciclovir